Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Towa Pharmaceutical Co ( (JP:4553) ) is now available.
Towa Pharmaceutical reported consolidated net sales of ¥204.1 billion for the nine months ended 31 December 2025, up 5.3% year on year, with operating profit rising 4.7% to ¥19.5 billion and profit attributable to owners of parent climbing 16.8% to ¥17.1 billion. Earnings per share advanced to ¥347.01, total assets and equity increased, and the company maintained its full-year forecast while planning higher annual dividends of ¥80 per share, signaling confidence in cash flow and shareholder returns.
The equity ratio improved to 38.8% from 36.5%, reflecting a stronger balance sheet that may enhance resilience and financing flexibility in a competitive pharmaceutical market. With no major changes in subsidiaries, accounting policies, or earnings guidance, Towa’s steady profit growth and dividend uplift highlight a stable operational trajectory that could appeal to income-focused and long-term investors.
The most recent analyst rating on (JP:4553) stock is a Buy with a Yen4337.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.
More about Towa Pharmaceutical Co
Towa Pharmaceutical Co., Ltd., listed on the Tokyo Stock Exchange, operates in the pharmaceuticals industry with a focus on prescription drugs. The company generates consolidated net sales exceeding ¥200 billion and targets both domestic and institutional markets, backed by a solid equity base and a rising equity ratio that underscores its financial stability.
Average Trading Volume: 125,571
Technical Sentiment Signal: Buy
Current Market Cap: Yen184.8B
Learn more about 4553 stock on TipRanks’ Stock Analysis page.